课题基金 / 基金详情

Cancer Clinical Epidemiology Training Grant

Cancer Clinical Epidemiology Training Grant
癌症临床流行病学培训补助金
批准号:
10555799
负责人:
Richard Aplenc
金额:
$52.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1992
资助国家:
美国
项目状态:
未结题
起止时间:
1992-09-01 至 2028-06-30

项目摘要

项目成果

Richard Aplenc的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 生物统计、流行病学和信息学系(DBEI)和艾布拉姆森癌症中心 (行政协调会),与医学部血液肿瘤科和 美国宾夕法尼亚大学佩雷尔曼医学院儿科肿瘤学系 医学(PSOM),建议继续实施创新、严格和成功的培训计划 癌症临床流行病学研究人员。每年需要五个博士后职位。 这一培训计划吸引了来自全国各地的实习生;其毕业生被安置在机构 在全国范围内,导致了一个影响很大的培训计划。培训计划的具体目标是:1) 培训下一代研究人员,以解决新的关键癌症流行病学问题 创新的分析方法和跨学科的研究协作;2)提供深入的知识 临床流行病学研究方法跨越癌症护理连续和寿命的研究问题; 3)提供密集的、受监督的研究经验,从而在导师的指导下出版第一批出版物 在儿童和成人癌症方面有积极的研究计划;以及4)促进流行病学之间的协同作用 流行病学以外的受训人员和研究人员通过在DBEI、ACC、 儿科和成人临床肿瘤科,以及宾夕法尼亚大学和CHOP的其他研究中心。 教学培训是通过临床流行病学理学硕士(MSCE)计划提供的 培训计划的负责人定期收到反馈,以优化每个研究员的进度。这个 严谨研究的主要概念在癌症基础流行病学方法课程中讲授。 分子流行病学和生物统计学,这是与受训者方法学兴趣相关的选修课; 由参与的教师、DBEI、ACC和成人组织的期刊俱乐部和临床研究会议 和儿科肿瘤科;独立阅读;负责任地进行研究的指导。 拟议计划的优点是:1)DBEI成功的研究培训计划的历史, ACC、成人和儿科肿瘤科,包括本培训计划;2)协作链接 对癌症临床研究感兴趣的教师;3)全面的课程设置和研究 学员可获得的课程;以及4)一批经验丰富、培训成功的教员 唱片。此外,许多现有的大型数据库可用于研究项目和培训;a 广泛的专业分析能力,可用于使用临床研究方法的临床研究 流行病学,以及教师对合作研究和培训的承诺,结合在一起,提供了一个理想的 此培训计划的环境。最后,PSOM促进了一个基本的和 临床研究受到鼓励,并被视为对医生有吸引力的职业道路。
英文摘要
PROJECT SUMMARY The Department of Biostatistics, Epidemiology and Informatics (DBEI) and the Abramson Cancer Center (ACC), in collaboration with the Division of Hematology-Oncology of the Department of Medicine and the Division of Oncology of the Department of Pediatrics, all at the University of Pennsylvania Perelman School of Medicine (PSOM), propose to continue an innovative, rigorous, and successful training program for investigators in cancer clinical epidemiology. Five postdoctoral positions per year are requested. This training program attracts trainees from across the country; its graduates are placed in institutions nationwide, resulting in a high impact training program. The specific aims of the training program are to: 1) train the next generation of investigators to address novel and critical cancer epidemiology questions with innovative analytic methods and transdisciplinary research collaborations; 2) provide in-depth knowledge of clinical epidemiology research methods for research questions across the cancer care continuum and lifespan; 3) provide intensive, supervised research experience resulting in first-authored publications with mentors who have active research programs in pediatric and adult cancer; and 4) promote synergies between epidemiology trainees and investigators outside of epidemiology through seminars and workshops offered at DBEI, the ACC, the pediatric and adult clinical oncology divisions, and other research centers at Penn and CHOP. Didactic training is provided through the Master of Science in Clinical Epidemiology (MSCE) program and the directors of the training program receive regular feedback to optimize the progress of each fellow. The principal concepts of rigorous research are taught in courses of fundamental epidemiological methods, cancer and molecular epidemiology, and biostatistics, elective courses relevant to the trainees’ methodologic interests; journal clubs and clinical research conferences conducted by participating faculty, the DBEI, ACC, and adult and pediatric oncology divisions; independent readings; and instruction in the responsible conduct of research. Strengths of the proposed program are: 1) the history of successful research training programs in the DBEI, ACC, and adult and pediatric oncology divisions, including this training program; 2) the collaborative links among faculty with interests in clinical research in cancer; 3) the comprehensive course offerings and research programs that are available to trainees; and 4) an extensive set of experienced faculty with successful training records. In addition, numerous existing large databases that can be used for research projects and training; a broad array of specialized analytic capabilities available for clinical studies employing methods of clinical epidemiology, and commitment of faculty to collaborative research and training, combine to provide an ideal environment for this training program. Finally, the PSOM promote an academic environment in which basic and clinical research are encouraged and viewed as attractive career paths for physicians.
期刊论文(61)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/phar.2463
发表时间: 2020-11
期刊: Pharmacotherapy
影响因子: 4.1
作者: [Varughese LA, Lau-Min KS, Cambareri C, Damjanov N, Massa R, Reddy N, Oyer R, Teitelbaum U, Tuteja S]
通讯作者: Tuteja S
Screening for colon cancer: a review of current and future strategies.
结肠癌筛查:当前和未来策略的回顾。
DOI: --
发表时间: 1995
期刊: Seminars in oncology.
影响因子: --
作者: [Weinberg,DS, Strom,BL]
通讯作者: Strom,BL
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
滤泡性淋巴瘤最佳一线治疗的决定因素:决策分析。
DOI: 10.1002/ajh.21655
发表时间: 2010
期刊: American journal of hematology
影响因子: 12.8
作者: [Olin,RebeccaL, Kanetsky,PeterA, TenHave,ThomasR, Nasta,SunitaD, Schuster,StephenJ, Andreadis,Charalambos]
通讯作者: Andreadis,Charalambos
Treatment and Outcomes of Oropharyngeal Cancer in People with Human Immunodeficiency Virus.
人类免疫缺陷病毒感染者口咽癌的治疗和结果。
DOI: 10.1089/aid.2019.0009
发表时间: 2019
期刊: AIDS research and human retroviruses
影响因子: 1.5
作者: [Brickman,CristinaE, Propert,KathleenJ, Merlin,JessicaS, Liu,JeffreyC, Eady,Sequoya, Mcghee-Jez,Amy, Ragin,Camille, Grover,Surbhi, Cohen,RogerB, Gross,Robert]
通讯作者: Gross,Robert
共 37 条
    Predicting and Monitoring for Cardiac Toxicity in Pediatric AML
    • 批准号:
      10659987
    • 项目类别:
    • 资助金额:
      $81.94万
    • 财政年份:
      2023
    • 负责人:
      Richard Aplenc
    • 依托单位:
    COG NCTN Network Group Operations Center
    • 批准号:
      10230669
    • 项目类别:
    • 资助金额:
      $270.2万
    • 财政年份:
      2014
    • 负责人:
      Richard Aplenc
    • 依托单位:
    COG NCTN Network Group Operations Center
    • 批准号:
      10221076
    • 项目类别:
    • 资助金额:
      $3.15万
    • 财政年份:
      2014
    • 负责人:
      Richard Aplenc
    • 依托单位:
    Toxicity Monitoring on Phase III Trials with Administrative Data
    • 批准号:
      8843803
    • 项目类别:
    • 资助金额:
      $41.03万
    • 财政年份:
      2012
    • 负责人:
      Richard Aplenc
    • 依托单位:
    海外基金